ArticleJournal of general internal medicine2025
Treatment of Inpatient Opioid Withdrawal with Short-Acting Full Agonist Opioids at a Safety-Net Hospital.
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Things We Do for No Reason™: Withholding opioids among patients with acute pain and opioid use disorder.Journal of hospital medicine · 2026Article
- Article
- Short-Acting Opioid Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder.JAMA network open · 2026Article
- The efficacy and safety of short-acting, full agonist opioids for symptom management of opioid withdrawal.Addictive behaviors reports · 2026Review
- Patient-Directed Discharge Among Hospitalized Persons With Opioid Use Disorder in the Fentanyl Era: A Scoping Review.American journal of medicine open · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFentanyl use leads to increased opioid tolerance in people with opioid use disorder, complicating management of opioid withdrawal syndrome. While accepted as gold standard, methadone and buprenorphine may be insufficient to treat acute opioid withdrawal. Short-acting full agonist opioids (SAFAO) may improve treatment in the acute care setting.
aimCharacterize use of SAFAO to treat opioid withdrawal syndrome for inpatients.
settingUrban safety-net hospital.
participantsInpatients with opioid use disorder. PROGRAM DESCRIPTION: Addiction Consult Team offers SAFAO to manage opioid withdrawal syndrome. PROGRAM EVALUATION: We performed retrospective chart review of hospitalizations (n = 124) for patients with opioid use disorder who received SAFAO between March and June 2023. Patients received methadone or buprenorphine during 94% of hospitalizations. On average, 278 mg (SD 407 mg) oral morphine equivalents (OMEs) of SAFAO were administered daily during the first hospitalization week. Daily Clinical Opiate Withdrawal Scale scores and SAFAO OMEs were inversely correlated (Spearman rank correlation = - 0.96, p = 0.003). Five hospitalizations exhibited adverse events (AEs). DISCUSSION: Use of methadone/buprenorphine did not alleviate the need for SAFAO, suggesting that SAFAO administration may be an important intervention for opioid withdrawal. Use of escalating OMEs of SAFAO was associated with reduced withdrawal severity. This practice was well-tolerated with few AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.